Caris Life Sciences, Inc. (CAI) Price & Analysis

Compare

65 Followers

CAI Stock Chart & Stats

Day’s Range― - ―

52-Week Range$25.40 - $33.41

Previous CloseN/A

VolumeN/A

Average Volume (3M)604.53K

Market Cap

$8.43B

Enterprise ValueN/A

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta0.35

Next Earnings

Aug 12, 2025

EPS EstimateN/A

Last Dividend Ex-Date

Sep 09, 2021

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding278,104,600

10 Day Avg. Volume469,120

30 Day Avg. Volume604,526

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$32.88

Price Target Upside17.26% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering8

Bulls Say, Bears Say

Bulls Say

Market PositionCaris Life Sciences holds a #1 market position in tissue-biopsy profiling, enhancing its competitive edge in the industry.

Revenue GrowthA higher reimbursement rate from Medicare has dramatically boosted Caris Life Sciences' revenue growth, moving the company closer to profitability.

Technological AdvantageThe unique Whole Exome Sequencing and Whole Transcriptome Sequencing technologies used by Caris target significantly more genes than competitive assays, providing unmatched depth for therapy selection.

Bears Say

Profitability ConcernsCaris Life Sciences has been assigned a High Risk rating due to the current lack of profitability and early-stage commercial payer negotiations, which could lead to stock volatility.

Valuation ConcernsCaris is trading at a premium valuation, which may pose risks if expected financial performance is not achieved.

Caris Life Sciences, Inc. News

Caris Life Sciences publishes new study on AI-based image analysis model

Caris Life Sciences (CAI) has published a new study in Communications Medicine, a Nature portfolio journal, demonstrating that...

2d ago

CAI

TER, NVDA, AMD: Cathie Wood Makes Million-Dollar Bets on AI and Robotics

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made million-dollar bets in the artificial intelligence (AI) and robotics sectors on July...

21d ago

AMD

CAI

ROKU, ACHR: Cathie Wood Offloads Millions in Roku and Archer Aviation Stocks

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made several interesting trades on Monday, July 14. The ace hedge fund manager...

24d ago

CAI

ACHR

Cathie Wood’s ARK Investment buys 52.5K shares of Caris Life Sciences today

20:46 EDT Cathie Wood’s ARK Investment buys 52.5K shares of Caris Life Sciences (CAI) today Published first on...

24d ago

CAI

Opening Day: several small IPOs hit market

A total of six companies went public last week. Globa Terra Acquisition, a blank check company with a...

25d ago

CAI

EGG

Caris Life Sciences initiated with a Buy at BTIG

BTIG analyst Mark Massaro initiated coverage of Caris Life Sciences (CAI) with a Buy rating and $38 price...

25d ago

CAI

Caris Life Sciences initiated with an Outperform at Wolfe Research

Wolfe Research initiated coverage of Caris Life Sciences (CAI) with an Outperform rating and $32 price target Caris...

25d ago

CAI

Caris Life Sciences initiated with a Buy at Citi

Citi initiated coverage of Caris Life Sciences (CAI) with a Buy rating and $34 price target The firm...

25d ago

CAI

Caris Life Sciences initiated with a Buy at TD Cowen

TD Cowen analyst Dan Brennan initiated coverage of Caris Life Sciences (CAI) with a Buy rating and $32...

25d ago

CAI

Caris Life Sciences initiated with an Outperform at Wolfe Research

Wolfe Research initiated coverage of Caris Life Sciences (CAI) with an Outperform rating and $32 price target Published...

25d ago

CAI

Caris Life Sciences initiated with a Buy at Guggenheim

Guggenheim initiated coverage of Caris Life Sciences (CAI) with a Buy rating and $32 price target The firm...

25d ago

CAI

Caris Life Sciences initiated with an Overweight at JPMorgan

JPMorgan analyst Rachel Vatnsdal initiated coverage of Caris Life Sciences (CAI) with an Overweight rating and $31 price...

25d ago

CAI

Strong Sales Growth and Strategic Market Expansion Drive Buy Rating for Caris Life Sciences

Caris Life Sciences, Inc. (CAI) has received a new Buy rating, initiated by TD Cowen analyst, Daniel Brennan....

25d ago

CAI

Caris Life Sciences: Strong Market Position and Growth Potential Justify Buy Rating

Michael Ryskin, an analyst from Bank of America Securities, has initiated a new Buy rating on Caris Life...

26d ago

CAI

CAI FAQ

What was Caris Life Sciences, Inc.’s price range in the past 12 months?

Caris Life Sciences, Inc. lowest stock price was $25.40 and its highest was $33.41 in the past 12 months.

What is Caris Life Sciences, Inc.’s market cap?

Caris Life Sciences, Inc.’s market cap is $8.43B.

When is Caris Life Sciences, Inc.’s upcoming earnings report date?

Caris Life Sciences, Inc.’s upcoming earnings report date is Aug 12, 2025 which is in 4 days.

How were Caris Life Sciences, Inc.’s earnings last quarter?

Currently, no data Available

Is Caris Life Sciences, Inc. overvalued?

According to Wall Street analysts Caris Life Sciences, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Caris Life Sciences, Inc. pay dividends?

Caris Life Sciences, Inc. pays a Quarterly dividend of $0.3 which represents an annual dividend yield of N/A. See more information on Caris Life Sciences, Inc. dividends here

What is Caris Life Sciences, Inc.’s EPS estimate?

Caris Life Sciences, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Caris Life Sciences, Inc. have?

Caris Life Sciences, Inc. has 278,104,600 shares outstanding.

What happened to Caris Life Sciences, Inc.’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Caris Life Sciences, Inc.?

Currently, no hedge funds are holding shares in CAI

Caris Life Sciences, Inc. Stock Smart Score

Outperform

Company Description

Caris Life Sciences, Inc.

Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and machine learning algorithms. The company's molecular profiling services portfolio includes MI Profile, a tissue-based molecular profiling solution; and Caris Assure, a blood-based molecular profiling solution for cancer treatment. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company was founded in 2008 and is headquartered in Irving, Texas.

Caris Life Sciences, Inc. (CAI) Earnings & Revenues

Historic Earnings Reports

CAI Stock 12 Month Forecast

Average Price Target

$32.88

▲(17.26% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"25":"$25","32":"$32","39":"$39","28.5":"$28.5","35.5":"$35.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$38.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":32.88,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$32.88</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":31,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$31.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[25,28.5,32,35.5,39],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.51,27.393846153846155,28.27769230769231,29.161538461538463,30.045384615384616,30.92923076923077,31.813076923076924,32.69692307692308,33.580769230769235,34.464615384615385,35.348461538461535,36.23230769230769,37.11615384615385,{"y":38,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.51,27,27.490000000000002,27.98,28.470000000000002,28.96,29.450000000000003,29.94,30.430000000000003,30.92,31.410000000000004,31.900000000000002,32.39,{"y":32.88,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.51,26.855384615384615,27.200769230769232,27.546153846153846,27.891538461538463,28.236923076923077,28.582307692307694,28.927692307692308,29.273076923076925,29.61846153846154,29.963846153846156,30.30923076923077,30.654615384615383,{"y":31,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":27.25,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.25,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.25,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.25,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.25,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.25,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.25,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.25,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.25,"date":1743465600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.25,"date":1746057600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.25,"date":1748736000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":26.51,"date":1751328000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":26.51,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >